Monitor serum LFTs (ALT & bilirubin levels) for at least 4 mth for evidence of recurrent hepatitis. Patients receiving immunosuppressive regimens; co-infected w/ HIV & currently or are planning to receive antiretroviral regimen. Transplantation recipient & advanced liver disease. Moderate to severe renal impairment. Pregnancy & lactation.
J05AF05 - lamivudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.